Piper Sandler Issues Positive Forecast for Edwards Lifesciences (NYSE:EW) Stock Price

Edwards Lifesciences (NYSE:EW) had its target price increased by Piper Sandler from $80.00 to $83.00 in a research note published on Tuesday morning, MarketBeat Ratings reports. The firm currently has an overweight rating on the medical research company’s stock.

EW has been the subject of several other reports. Robert W. Baird upped their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a research report on Thursday, April 24th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a report on Friday, April 25th. StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday, May 8th. Evercore ISI lowered their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Finally, Truist Financial dropped their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Hold” and a consensus price target of $79.60.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $76.79 on Tuesday. The firm has a 50 day moving average of $71.89 and a 200-day moving average of $71.67. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $45.05 billion, a PE ratio of 11.02, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.66 earnings per share. On average, equities research analysts predict that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $70.78, for a total value of $796,275.00. Following the transaction, the chief financial officer now owns 30,387 shares in the company, valued at approximately $2,150,791.86. The trade was a 27.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the company’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer now directly owns 58,284 shares in the company, valued at approximately $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,192 shares of company stock worth $4,709,454. Insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Large investors have recently bought and sold shares of the business. Prosperity Consulting Group LLC boosted its position in shares of Edwards Lifesciences by 3.6% during the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company’s stock valued at $289,000 after purchasing an additional 134 shares in the last quarter. Arlington Trust Co LLC increased its holdings in Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock worth $804,000 after purchasing an additional 135 shares in the last quarter. Abacus Planning Group Inc. lifted its stake in Edwards Lifesciences by 0.3% in the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company’s stock valued at $2,977,000 after buying an additional 140 shares during the period. Valeo Financial Advisors LLC lifted its stake in Edwards Lifesciences by 2.8% in the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after buying an additional 142 shares during the period. Finally, Versant Capital Management Inc grew its position in shares of Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock worth $123,000 after buying an additional 145 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.